News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Handelsbanken Fonder AB significantly increased its stake in Axsome Therapeutics, Inc. by 216.4% in the second quarter, now holding 42,400 shares valued at $10.38 million. This comes despite Axsome Therapeutics missing analyst expectations for both earnings and revenue in its latest quarterly report. The …
Mizuho has increased its target price for Axsome Therapeutics, Inc. to $316, up from the previous $306. This adjustment indicates a positive outlook from the analyst firm regarding the biopharmaceutical company's future performance.
Axsome Therapeutics reported Q2 revenues of US$218m, meeting expectations, but statutory losses per share were higher at US$0.99. Analysts reconfirmed revenue forecasts for 2026 at US$972.9m, a 25% increase, but expanded per-share loss expectations to US$2.62. Despite the mixed outlook, the consensus price target …
Axsome Therapeutics (NASDAQ:AXSM) has received a consensus "Moderate Buy" rating from 22 brokerages, with an average 12-month price target of $267.60, significantly above its current trading price of $214.66. This comes despite the company missing its latest quarterly earnings expectations, reporting a wider loss …
UBS has increased its price target for Axsome Therapeutics (NASDAQ: AXSM) to $280 from $259, while maintaining a Buy rating on the stock. This adjustment reflects UBS's continued positive outlook on the biopharmaceutical company. Separately, Mizuho also adjusted its price target for Axsome Therapeutics …
Quantinno Capital Management LP increased its stake in Axsome Therapeutics (NASDAQ:AXSM) by 77.5% in the first quarter, purchasing an additional 5,019 shares and bringing its total holdings to 11,497 shares valued at $1.94 million. Despite revenue growth driven by Auvelity sales, Axsome Therapeutics missed …
Axsome Therapeutics (AXSM) reported Q2 revenue of US$218.4m, driven by its neurology brands, but also posted a net loss of US$51.3m, causing a slight stock pullback. While revenue growth is strong, particularly from AUVELITY, concerns remain about profitability due to high gross-to-net discounts, rising …
Axsome Therapeutics AXSM incurred a loss of 99 cents per share in the second quarter of 2026, which was in line with the Zacks Consensus Estimate. The company had reported a loss of 97 cents per share in the year-ago quarter. Axsome's total revenues …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Axsome Therapeutics earnings event and why it matters Axsome Therapeutics (AXSM) just reported second quarter 2026 results, with revenue of US$218.38 million and a net …
Somnigroup International (SGI) faces a mixed operating environment with growth opportunities from acquisitions and cash generation, but also challenges from weak bedding demand, margin pressures, and execution risks. While the company benefits from its vertically integrated platform and synergies from the Mattress Firm acquisition, …
Search by ticker symbol or company name and select a result to open its chart.